Related Experiment Video
Updated: Sep 20, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Phase II clinical trial of oxaliplatin alone for refractory advanced colorectal cancer]
Rui-Hua Xu1, Zhong-Zhen Guan, Feng-Yi Feng
1Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China. ruihuaxu@163.net
Background & Objective:
Oxaliplatin is effective for the advanced colorectal cancer (CRC) as a second-line drug; however, the efficiency and adverse reaction of oxaliplatin made in China are not yet clear. The aim of this project was to evaluate the efficacy and the toxicities of oxaliplatin made in China in the treatment of the patients with advanced CRC who were resistant to 5-fluorouracil (5-Fu).
Methods:
The previously 5-FU-resistant patients with CRC were treated with single agent of oxaliplatin 130 mg/m(2), i.v., d1, repeated every 3 weeks.
Results:
A total of 31 cases with advanced CRC resistant to 5-Fu were enrolled, and 28 cases were valuable for efficacy assessment. One patient reached complete response (CR), 3 reached partial response (PR), and the overall response rate was 14.29% (with ITT equal to 12.9%). The major adverse effects were mild neuro-sensory toxicity, mild myelosuppression,and nausea/vomiting.
Conclusion:
The oxaliplatin made in China is effective in the treatment of advanced CRC resistant to 5-Fu, and the adverse effects are mild.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Treatment Resistent Cancers
